About Arsia Therapeutics
Arsia Therapeutics is a Healthcare company based in Waltham (United States) founded in 2013, and was acquired by Eagle Pharmaceuticals in November 2016. High-concentration biologics are formulated for low-viscosity subcutaneous injection. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Arsia Therapeutics was founded in 2013 and is located in Waltham, United States. A platform technology for protein formulation is utilized to develop high-concentration, low-viscosity drug products. Biologics requiring intravenous infusion are thereby enabled for subcutaneous administration or delivery through autoinjector pens or patch pumps. Collaborations with more than 10 pharmaceutical and biotechnology companies have resulted in viscosity reductions for antibodies, fusion proteins, and other biologics.
- Headquarters Waltham, United States
- Stage Acquired
- SectorsHealthcare
- Website arsiarx.com
- Acquired by Eagle Pharmaceuticals (Nov 2016)
- Investors
- Acquired byEagle Pharmaceuticals
(Nov 2016)
Investors in Arsia Therapeutics
Arsia Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eagle Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops injectable products for use in critical care, orphan diseases, and oncology | 2007 | eagleus.com | Woodcliff Lake, United States |
Investor details for Arsia Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Arsia Therapeutics
2 dated milestones of Arsia Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Arsia Therapeutics is founded.
- Exit Acquired by Eagle Pharmaceuticals.
Competitors of Arsia Therapeutics
Arsia Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Arsia Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Arsia Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Arsia Therapeutics
Arsia Therapeutics was founded in 2013.
Arsia Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Arsia Therapeutics was founded in 2013 and is located in Waltham, United States. A platform technology for protein formulation is utilized to develop high-concentration, low-viscosity drug products. Biologics requiring intravenous infusion are thereby enabled for subcutaneous administration or delivery through autoinjector pens or patch pumps. Collaborations with more than 10 pharmaceutical and biotechnology companies have resulted in viscosity reductions for antibodies, fusion proteins, and other biologics.
Arsia Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Arsia Therapeutics has 1 investor. Key investors include Eagle Pharmaceuticals.
Yes. Arsia Therapeutics was acquired by Eagle Pharmaceuticals in November 2016.